ClinicalTrials.gg
Not yet recruitingNCT07931248Updated Nov 12, 2026

Investigating ELSI Issues That May Facilitate or Impede Clinical Translation of Epigenetic Research.

An interventional study of Analogy Video and Epigenetics Video in Healthy, sponsored by Washington University School of Medicine. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Washington University School of Medicine · Not applicable, Interventional, and Other

Updated Nov 12, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
720
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Few people realize that environmental pollution and some behaviors like physical activity and tobacco smoking can affect their health by "turning on" or "turning off" certain genes through a process called "epigenetic modification." This study will develop and test strategies for communicating about epigenetics that are understandable and that do not increase ethical, legal or social issues (ELSI).

02

Conditions studied

  • Healthy

Browse trials for

Keywords

  • Epigenomics
  • Epigenetics
  • Genetics, Behavioral
  • Bioethics
03

In context

Behavior

1,574 studies on the registry are indexed under Behavior; 314 are open to participants now.

This study's planned enrollment of 720 is above the median of 120 across 1,198 interventional studies indexed under Behavior.

Browse Behavior studies →

Lead sponsor

Washington University School of Medicine is the lead sponsor of 1,804 studies on the registry; 270 are open to participants now.

Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • English-language speaker

Exclusion criteria

Exclusion Criteria:

  • Not a self reported expert in genetics
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
720 participants (estimated)

Study arms

  • Active comparator
    Epigenetics Video

    Participants will watch a brief (\<5 minute) video about the concept of Epigenetics

    Behavioral: Epigenetics Video

  • Experimental
    Analogy Video

    Participants will watch a brief (\<5 minute) video about the concept of Epigenetics as well as a brief (\<1 minute) video using an analogy to describe epigenetics.

    Behavioral: Analogy Video

Interventions

  • BehavioralAnalogy Video

    Video using an analogy to explain epigenetics.

  • BehavioralEpigenetics Video

    Video explaining the concept of epigenetics.

06

What researchers measure

Primary outcomes

  1. Knowledge & understanding of epigenetics Information

    Sum score of correct answers for 11 individual items. Scale ranges from 0 points to 11 points with higher scores indicating higher epigenetics knowledge.

    Time frame: Baseline

Secondary outcomes

  1. Acceptability of epigenetics information

    Three constructs including perceived benefits of epigenetic research (7 items, ranging from 1 to 5 with higher scores indicating higher perceived benefits), perceived drawbacks of epigenetic research (3 items, ranging from 1 to 5 with higher scores indicating higher perceived drawbacks), and acceptance of using epigenetic research in medical support (3 items, ranging from 1 to 5 with higher scores indicating higher acceptance of using epigenetic research in medical support).

    Time frame: Baseline

  2. Perceptions of epigenetic information

    6 item scale where scores range from 1 to 5, with higher scores indicating greater perceptions of epigenetic information.

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Feb 2027, 1 month later.

Of 741 non-industry interventional studies with no phase under Behavior, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 1 month is below that.

Counting every sponsor, half of 757 studies reached it within 14 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2026
First posted
Nov 12, 2026
StartEst.
Jan 2, 2027
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07931248
Responsible party
Sponsor
First posted
Nov 12, 2026
Start date
Jan 2, 2027 (estimated)
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Julia Maki, PhD
Contact
jmaki@wustl.edu
314-286-2835
Erika Waters, PhD, MPH
Contact
waterse@wustl.edu
314-747-5705

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion